Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Sana Biotechnology has a “Moderate Buy” consensus rating from nine analysts, with seven buys, one hold and one sell. The average 12-month price target is $9.50, well above the stock’s recent $3.18 price.
• Institutional investors and hedge funds own 88.23% of the company, with several firms recently initiating or increasing their positions.
• Sana is a clinical-stage biopharmaceutical company developing engineered cell therapies for cancer, genetic disorders and other serious diseases. It reported quarterly EPS of -$0.14, slightly better than the -$0.15 consensus estimate, while analysts expect full-year EPS of -$0.59.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $9.50.

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Monday, July 20th. Weiss Ratings raised Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday. Wedbush lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Tuesday, April 14th. Finally, Rodman & Renshaw initiated coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a "buy" rating and a $16.00 price target for the company.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently made changes to their positions in the company. Royal Bank of Canada grew its position in Sana Biotechnology by 76.8% during the first quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock valued at $35,000 after buying an additional 5,338 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in Sana Biotechnology in the third quarter valued at $36,000. Rockefeller Capital Management L.P. raised its position in shares of Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after acquiring an additional 4,088 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Sana Biotechnology in the third quarter worth about $39,000. Finally, LRI Investments LLC purchased a new stake in shares of Sana Biotechnology during the 4th quarter worth about $41,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.18 on Monday. The stock has a market cap of $884.96 million, a PE ratio of -3.42 and a beta of 2.13. The firm has a fifty day moving average price of $3.26 and a 200 day moving average price of $3.57. Sana Biotechnology has a 1 year low of $2.61 and a 1 year high of $6.55.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, equities analysts expect that Sana Biotechnology will post -0.59 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.